- Home
- LW vs VRNA Comparison
LW vs VRNA Comparison
Compare LW & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LW
- VRNA
- Stock Information
- Founded
- LW 1950
- VRNA 2005
- Country
- LW United States
- VRNA United Kingdom
- Employees
- LW N/A
- VRNA N/A
- Industry
- LW Packaged Foods
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- LW Consumer Staples
- VRNA Health Care
- Exchange
- LW Nasdaq
- VRNA Nasdaq
- Market Cap
- LW 8.2B
- VRNA 8.3B
- IPO Year
- LW N/A
- VRNA 2017
- Fundamental
- Price
- LW $56.96
- VRNA $105.15
- Analyst Decision
- LW Buy
- VRNA Buy
- Analyst Count
- LW 11
- VRNA 11
- Target Price
- LW $68.91
- VRNA $114.10
- AVG Volume (30 Days)
- LW 2.9M
- VRNA 8.0M
- Earning Date
- LW 07-23-2025
- VRNA 08-11-2025
- Dividend Yield
- LW 2.53%
- VRNA N/A
- EPS Growth
- LW N/A
- VRNA N/A
- EPS
- LW 2.50
- VRNA N/A
- Revenue
- LW $6,451,300,000.00
- VRNA $118,535,000.00
- Revenue This Year
- LW $2.61
- VRNA $893.95
- Revenue Next Year
- LW $3.23
- VRNA $73.76
- P/E Ratio
- LW $23.42
- VRNA N/A
- Revenue Growth
- LW N/A
- VRNA N/A
- 52 Week Low
- LW $47.87
- VRNA $18.51
- 52 Week High
- LW $83.98
- VRNA $105.50
- Technical
- Relative Strength Index (RSI)
- LW 61.84
- VRNA 70.43
- Support Level
- LW $47.87
- VRNA $104.58
- Resistance Level
- LW $61.02
- VRNA $105.31
- Average True Range (ATR)
- LW 1.78
- VRNA 0.23
- MACD
- LW 0.93
- VRNA -0.60
- Stochastic Oscillator
- LW 78.48
- VRNA 67.39
About LW Lamb Weston Holdings Inc.
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 14% of fiscal 2024 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.